A Form 4 filed on September 10, 2026 with the U.S. Securities and Exchange Commission disclosed that Joseph Truitt, a newly appointed director of Century Therapeutics, Inc. (NASDAQ:IPSC), was granted 148,000 stock options on September 9, 2026 in connection with his appointment to the board.

Key Highlights

  • Reporting Person: Joseph Truitt, identified as a Director of Century Therapeutics, Inc.
  • Grant Date: Options were awarded on September 9, 2026.
  • Options Granted: 148,000 stock options (right to buy) with an exercise price of $2.03 per share.
  • Expiration Date: The options expire on September 9, 2036.
  • Vesting Schedule: Options vest in equal monthly installments over 36 months, subject to continued service.
  • Plan: Options were issued under the Company's 2021 Equity Incentive Plan.
  • Price Paid: The price of the derivative security at grant was $0.

Director Grant Details for Joseph Truitt at Century Therapeutics

According to the Form 4 filing, Joseph Truitt received a grant of 148,000 stock options from Century Therapeutics, Inc. on September 9, 2026. The filing states that the options were issued "in connection with his appointment as a director." The exercise price of the options is $2.03 per share, and the options carry an expiration date of September 9, 2036, giving them a ten-year term from the date of grant.

The filing discloses that the options vest in equal monthly installments over 36 months, contingent on the reporting person's continued service to the company. The grant was made pursuant to Century Therapeutics' 2021 Equity Incentive Plan. The price of the derivative security at the time of the transaction was reported as $0. Following the reported transaction, Truitt beneficially owns 148,000 derivative securities directly, with no prior holdings reported in the filing.

The Form 4 was filed on September 10, 2026, and was signed by Douglas Carr as Attorney-in-Fact on behalf of the reporting person. The filing indicates this was made by one reporting person and does not reflect any amendment to a prior filing.

What Was Disclosed

Century Therapeutics disclosed the grant of 148,000 stock options to newly appointed director Joseph Truitt at an exercise price of $2.03, expiring September 9, 2036, vesting monthly over 36 months under the company's 2021 Equity Incentive Plan.